Faculty in How I Treat Difficult RA: Panel Session reviewed difficult-to-treat cases for RA patients with ILD, refractory RA, and RA with liver disease.

Quantifying the severity of SLE damage remains a challenge, and an ACR Convergence 2020 session discussed issues pertaining to the development of an improved strategy.

As more and more patients with rheumatic diseases turn to the digital world for information and support, rheumatologists and their care teams need to know how to guide their patients toward reputable information and away from potentially harmful outcomes.

Calcium pyrophosphate (CCP) arthritis was first described more than 50 years ago. Since then, researchers have found that this extremely painful type of arthritis is extraordinarily common but significantly underdiagnosed.

The microbiome presents a tremendous opportunity for understanding disease because it’s able to be manipulated once you find the right way, but there’s still so much unknown about finding the right way to manipulate the microbiome.

Research continues into finding ways to treat rheumatoid arthritis early enough to delay the onset of symptoms or possibly reverse the course of the disease entirely and keep arthritis from developing.

Only in the past 15 years or so have people accepted the idea that molecular targeting could lead to disease modification in osteoarthritis, and an ACR Convergence 2020 educational session will cover the latest targets in preclinical models and early phase trials involving both mice and humans.

The education session Reproductive Health: Meet Women’s Needs features three speakers who not only work with patients with rheumatic disease but are also mothers who live with a rheumatic disease.

MEET THE POSTER PRESENTER: SSc is a severe rheumatic disease with high mortality from lung and heart disease, and major non-lethal clinical burden, including fibrosis of the skin. Sampling skin gives a unique opportunity to explore local disease mechanisms and better understand pathogenesis.